Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01164332
Recruitment Status : Completed
First Posted : July 16, 2010
Last Update Posted : June 10, 2015
Information provided by (Responsible Party):

Brief Summary:

The disposition of NRL972 after a 15-second intravenous injection of 2 mg NRL972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects. NRL972 appears to be a suitable investigational marker of hepatic transporter clearance dysfunction.

Although the pharmacokinetics of NRL972 provide a reliable differentiation between subject groups, this approach relies on precisely timed sampling of venous blood, cautious preparation, handling and on-site storage of plasma samples, the transfer of samples to a central laboratory for analysis, and the availability of a validated assay procedure.

For these reasons, there is interest in developing and validating alternative methods for determining the concentration of NRL972 in venous blood. Two such methods have been developed to date, but their utility in determining NRL972 pharmacokinetics has yet to be established.

Condition or disease Intervention/treatment Phase
Cirrhosis Other: NRL972 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Investigation of the Sensitivity of Different Methods to Detect NRL972 in Healthy Volunteers During and After a 2-hour Intravenous Infusion of 10 and 30mg NRL972
Study Start Date : July 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Method A
First experimental detection method
Other: NRL972
Two-hour intravenous infusion of 5 and 15 mg per hour

Method B
Second experimental detection method
Other: NRL972
Two-hour intravenous infusion of 5 and 15 mg per hour

Primary Outcome Measures :
  1. Ratios of the plasma concentration at 30 minutes post-infusion to the concentrations at 10 and 15 minutes post-infusion [ Time Frame: Up to 4 hours post-dose ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Up to 4 hours post-dose ]
  2. Vital signs [ Time Frame: Up to 4 hours post-dose ]
  3. ECG [ Time Frame: Up to 4 hours post-dose ]
  4. Clinical laboratory blood tests [ Time Frame: Up to 4 hours post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Subjects meeting the following conditions will be eligible for enrolment:

  • Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)
  • Caucasian
  • Age: 20 to 45 years
  • BMI 20 - 26 kg.m-2
  • Healthy based on the pre-study examination
  • Suitable veins for easy cannulation
  • Willing and able to provide informed consent

Exclusion Criteria:

Subjects of any of the following categories will be excluded from enrolment:

General - all subjects

  • Previous participation in the trial
  • Participant in any other trial during the last 90 days
  • Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
  • History of any clinically relevant allergy
  • Presence of any acute or chronic infection
  • Presence or history of any relevant co-morbidity
  • Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg
  • Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular
  • Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes
  • Positive serology for HBsAg, anti HBc and anti HCV
  • Positive HIV test
  • Positive alcohol or urine drug test on recruitment
  • History of alcohol and/or drug abuse and/or daily use of > 30 g alcohol
  • Smoking more than 10 cigarettes/day or equivalent of other tobacco products
  • Use of prohibited medication
  • Suspicion or evidence that the subject is not trustworthy and reliable
  • Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

General - all females

  • Positive pregnancy test
  • Lactating
  • Not using appropriate contraception in premenopausal women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01164332

Layout table for location information
Phase I-II study clinical of the Drug Research Center Ltd.
Balatonfüred, Hungary, H-8230
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Eva Peterfai, MD Drug Research Center Ltd.

Layout table for additonal information
Responsible Party: Norgine Identifier: NCT01164332    
Other Study ID Numbers: NRL972-01/2010 (AMET)
First Posted: July 16, 2010    Key Record Dates
Last Update Posted: June 10, 2015
Last Verified: July 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes